Navigation Links
BioCryst Reports Fourth Quarter and Year End 2008 Financial Results and Provides Corporate Update
Date:2/6/2009

n of the Company's collaboration with Roche, and increases in personnel related costs, professional fees and operating costs.

G&A expenses were $10.4 million for the year ended December 31, 2008, compared to $9.5 million for the year ended December 31, 2007. The higher expenses were primarily due to increases in professional fees and operating costs.

The net loss for the year ended December 31, 2008, was $24.7 million, or $0.65 per share, compared to a net loss for the year ended December 31, 2007, of $29.1 million, or $0.89 per share.

As of December 31, 2008, the Company held cash, cash equivalents and investments of $63.3 million, which is in-line with the Company's 2008 guidance. BioCryst expects the Company's net cash use in 2009 will be between $30.0 and $38.0 million, dependent on the achievement of certain clinical milestones.

"We made significant headway in our clinical programs in 2008 and have a cash position that will enable us to fund our clinical programs well into 2010," stated Jon Stonehouse, President and Chief Executive Officer of BioCryst. "We were pleased to report positive data, from both our internal and partnered peramivir programs, and look forward to evaluating the data from our ongoing peramivir trials. In 2009, we hope to report top-line data from our Phase 2 trial of peramivir in outpatient influenza and subsequently initiate a Phase 3 program in this indication, and will continue to progress our PNP programs."

Recent Clinical and Corporate Highlights

Peramivir Program

  • BioCryst's Phase 2 study of i.m. peramivir in the outpatient setting continues to enroll patients in the Northern Hemisphere. The Company expects to report top-line data from this study in the second quarter of 2009.

  • BioCryst's partner, Shionogi, has initiate
    '/>"/>

SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. BioCryst to Present at the BioCentury NewsMakers in the Biotech Industry Conference
2. BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza
3. BioCryst to Present at UBS 2007 Global Life Sciences Conference
4. BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities
5. BioCryst Pharmaceuticals to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on March 4, 2008
6. BioCryst Reports Fourth Quarter and Year End 2007 Financial Results and Corporate Update
7. BioCryst Reports First Quarter 2008 Financial Results and Clinical Update
8. William P. Sheridan Appointed Chief Medical Officer of BioCryst Pharmaceuticals
9. BioCryst Pharmaceuticals To Announce Second Quarter 2008 Financial Results on August 7, 2008
10. BioCryst to Present at UBS 2008 Global Life Sciences Conference
11. BioCryst to Present at the JMP Healthcare Focus Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... 20, 2014 Not long ago, it ... should be performed late in the development cycle – ... current regulatory trends suggest that, like many things GxP, ... In recent years, multiple drug sponsors have been required ... specific questions during phase I/II. It’s not only clinical ...
(Date:8/20/2014)... GraphDB™ 6.0 from ... to the enterprise replication cluster, faster loading speeds, ... and Elasticsearch. This release happens to coincide with ... – GraphDB™ was formerly known as OWLIM. ... mature enterprise resilient RDF triplestore will also benefit ...
(Date:8/19/2014)... Aug. 19, 2014 A Geisinger researcher on ... for a Centers for Disease Control and Prevention (CDC) ... public health concern. Joseph Boscarino , ... of a team of researchers nominated for the Centers ... Science Award for Data Methods and Study Design. ...
(Date:8/19/2014)... KS (PRWEB) August 19, 2014 ... offer fast and cost-effective metabolite production from bioactive ... proprietary chemistry platform, the technology enables convenient and ... According to XenoTech’s Vice President of Commercial ... synthesis for assessing clinical risk can be measured ...
Breaking Biology Technology:Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 3Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 4Geisinger investigator nominated for federal award 2Geisinger investigator nominated for federal award 3Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 2Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 3
... BEIJING and CLAREMONT, Calif., Jan. 7 /Xinhua-PRNewswire-FirstCall/ ... that: Xinjiang,Corps Agro-technology Extended Terminal promulgated the ... Shou" and "Jin Peng Jia Bao", both ... official fertilizer,certificate replaces the previous Temporary Amino ...
... Germany and OXFORD, England, January 7 /PRNewswire-FirstCall/,-- Evotec ... it has,successfully completed a Phase I safety and ... the good tolerability profile of EVT,302 and are ... EVT 302, a reversible and highly selective inhibitor ...
... Vical Incorporated,(Nasdaq: VICL ) today announced that ... in a panel discussion on biodefense and,pandemic influenza ... (San Francisco, CA - January 7-10)., The ... Long & Aldridge LLP.,Co-keynotes for the session are ...
Cached Biology Technology:Kiwa Fertilizers Pass Independent Tests 2Kiwa Fertilizers Pass Independent Tests 3Phase I Safety and Tolerability Study With EVT 302 Successfully Completed 2Phase I Safety and Tolerability Study With EVT 302 Successfully Completed 3Phase I Safety and Tolerability Study With EVT 302 Successfully Completed 4Phase I Safety and Tolerability Study With EVT 302 Successfully Completed 5Vical to Participate in Pandemic Influenza Panel at JPMorgan Healthcare Conference 2
(Date:8/20/2014)... (August 20, 2014) Women who are poor experience ... infants with elevated levels of the stress hormone, ... in life, according to a new research from the ... recently in the American Journal of Human Biology ... and relate it directly to the socioeconomic status of ...
(Date:8/20/2014)... to about 4,000 members, it triggers an important first ... special type of comb used for rearing male reproductive, ... of Neurobiology and Behaviour at Cornell University, led by ... honeybee colonies. The results are published in Springer,s journal ... , Reproduction isn,t always a honeybee colony,s top priority. ...
(Date:8/20/2014)... light and its energy is finally utilized for ... devices, mostly build from silicon based semiconductors, also ... for the development of cheaper and renewable photovoltaics ... membrane protein complexes of photosynthesis. Prof. Dr. Matthias ... thermophilic cyanobacteria that live in a hot spring ...
Breaking Biology News(10 mins):CU Denver researcher shows economic disparities impact infant health 2Worker bees 'know' when to invest in their reproductive future 2A semi-artificial leaf faster than 'natural' photosynthesis 2
... identify MRSA in wounds could identify the superbug quickly and ... test to show whether wounds or lesions are infected with ... at the University of Edinburgh in collaboration with NHS Lothian, ... are then analysed using a strip with electrical sensors that ...
... a polar bear. They may have to go months without eating. ... catch. Add to that the melting of Arctic sea ice due ... chemicals, and it,s easy to see why polar bears worldwide are ... one possible bright spot. In a study of PCBs in polar ...
... Many consumers want to increase their intake of heart-healthy ... products, but find it difficult to consume the levels ... Virginia Tech have demonstrated that it may be possible ... serving of a savory-flavored yogurt, providing an easily incorporated ...
Cached Biology News:Tiny electrical sensors could signal faster MRSA diagnosis 2PCBs levels down in Norwegian polar bears 2PCBs levels down in Norwegian polar bears 3Fish oil added to yogurt may help consumers meet daily nutritional requirements 2
...
... PowerEase 500 Power Supply is ... It offers extensive programming capabilities ... custom methods for you to ... The simple intuitive PowerEase interface ...
... Transformation Buffer Set are convenient methods for ... for simple and highly efficient DNA transformation. ... for heat shocking and related procedures. Instead, ... adding DNA to Z-Competent cells and incubating ...
Buffer used for mitocapture assays....
Biology Products: